AMYT
Income statement / Annual
Last year (2021), Amryt Pharma plc's total revenue was $222.54 M,
an increase of 21.87% from the previous year.
In 2021, Amryt Pharma plc's net income was -$18.17 M.
See Amryt Pharma plc,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
FY-2013
|
FY-2012
|
| Period Ended |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
03/31/2015 |
03/31/2014 |
03/31/2013 |
03/31/2012 |
| Operating Revenue |
$222.54 M |
$182.61 M |
$58.12 M |
$16.53 M |
$15.33 M |
$1.42 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$106.12 M
|
$119.03 M
|
$42.00 M
|
$6.06 M
|
$6.45 M
|
$616,297.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
$116.42 M
|
$63.58 M
|
$16.12 M
|
$10.47 M
|
$8.88 M
|
$804,551.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit Ratio |
0.52
|
0.35
|
0.28
|
0.63
|
0.58
|
0.57
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$37.73 M
|
$27.62 M
|
$15.83 M
|
$10.35 M
|
$12.67 M
|
$2.47 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| General & Administrative Expenses |
$8.34 M
|
$4.73 M
|
$841,000.00
|
$17.57 M
|
$13.25 M
|
$4.25 M
|
$3.33 M
|
$2.93 M
|
$1.87 M
|
$275,371.00
|
| Selling & Marketing Expenses |
$92.00 M
|
$76.67 M
|
$35.50 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$100.34 M
|
$81.40 M
|
$36.34 M
|
$17.57 M
|
$13.25 M
|
$4.25 M
|
$3.33 M
|
$2.93 M
|
$1.87 M
|
$275,371.00
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$138.07 M
|
$109.02 M
|
$52.17 M
|
$27.92 M
|
$25.93 M
|
$6.95 M
|
$3.34 M
|
$2.93 M
|
$1.86 M
|
$275,371.00
|
| Cost And Expenses |
$244.18 M
|
$228.05 M
|
$94.17 M
|
$33.98 M
|
$32.37 M
|
$7.57 M
|
$3.34 M
|
$2.93 M
|
$1.86 M
|
$275,371.00
|
| Interest Income |
$5,000.00
|
$87,000.00
|
$92,000.00
|
$5,719.51
|
$5,998.51
|
$1,051.70
|
$185,000.00
|
$201,000.00
|
$319,071.00
|
$0.00
|
| Interest Expense |
$27.91 M
|
$19.57 M
|
$8.48 M
|
$1.78 M
|
$989,754.00
|
$127,255.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$50.74 M
|
$44.47 M
|
$12.63 M
|
$354,609.00
|
$310,722.00
|
$204,030.00
|
$6,000.00
|
$6,000.00
|
$4,558.16
|
$0.00
|
| EBITDA |
$29.10 M |
-$977,000.00 |
-$23.42 M |
-$17.09 M |
-$16.73 M |
-$5.94 M |
$33.26 M |
-$3.10 M |
-$1.27 M |
-$275,371.83 |
| EBITDA Ratio |
0.13
|
-0.01
|
-0.4
|
-1.03
|
-1.09
|
-4.18
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
-0.1
|
-0.25
|
-0.62
|
-1.06
|
-1.11
|
-5.69
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
-$8.17 M
|
-$60.42 M
|
-$30.72 M
|
-$12.00 M
|
-$14.31 M
|
-$127,255.90
|
$189,000.00
|
-$36.81 M
|
$376,000.00
|
-$1.84 M
|
| Income Before Tax |
-$29.81 M
|
-$105.86 M
|
-$66.76 M
|
-$29.45 M
|
-$31.36 M
|
-$8.21 M
|
-$39.74 M
|
-$2.56 M
|
-$2.12 M
|
-$275,371.83
|
| Income Before Tax Ratio |
-0.13
|
-0.58
|
-1.15
|
-1.78
|
-2.05
|
-5.78
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
-$11.64 M
|
-$1.33 M
|
-$1.23 M
|
$41,180.00
|
$14.31 M
|
$1.93 M
|
$73.18 M
|
-$175,000.00
|
$2.23 M
|
$550,743.00
|
| Net Income |
-$18.17 M
|
-$104.53 M
|
-$65.54 M
|
-$29.49 M
|
-$45.67 M
|
-$8.21 M
|
-$39.74 M
|
-$2.56 M
|
-$2.12 M
|
-$826,115.50
|
| Net Income Ratio |
-0.08
|
-0.57
|
-1.13
|
-1.78
|
-2.98
|
-5.78
|
0
|
0
|
0
|
0
|
| EPS |
-0.39 |
-2.92 |
-4.32 |
-3.22 |
-6.14 |
-1.51 |
-3.45 |
-0.26 |
-0.33 |
-0.0816 |
| EPS Diluted |
-0.37 |
-2.92 |
-4.32 |
-3.22 |
-6.14 |
-1.51 |
-3.45 |
-0.26 |
-0.33 |
-0.0816 |
| Weighted Average Shares Out |
$47.17 M
|
$35.76 M
|
$15.17 M
|
$9.16 M
|
$7.44 M
|
$5.44 M
|
$11.51 M
|
$9.81 M
|
$6.47 M
|
$10.12 M
|
| Weighted Average Shares Out Diluted |
$49.40 M
|
$35.76 M
|
$15.17 M
|
$9.16 M
|
$7.44 M
|
$5.44 M
|
$11.51 M
|
$9.81 M
|
$6.47 M
|
$10.12 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
